News

Network aims to improve end-to-end supply chain visibility for the life sciences industry.

Rise in value attributed to the ongoing decentralization of pharmacies.

Deal is expected to boost company’s market access capabilities.

Numbers point to a 2.9% boost over pre-pandemic records.

Manufacturing plant is expected to produce 500 million vaccine doses annually.

Deal is expected to offer airline with additional variety when it comes to shipping temperature-sensitive pharma products.

The latest people news happenings over the past month.

Senate committee report highlights a lack of visibility in API suppliers.

Amid continued tussling over drug costs, a new working group will review the government’s authority to revoke licenses for medical products.

Industry is still scrambling to handle clerical errors of DSCSA transactions.

Event—taking place in Indianapolis—places supply chain education at the forefront.

The Pulse online service will provide free resources to enable pharmacy to meet drug traceability rules.

Q&A explores new opportunities to strengthen supply chain resilience—and build on the lessons learned.

Project addresses customer demand in GMP-powered advanced therapeutics.

In an effort to strengthen supply chain, unnamed pharma company to use chain of custody application to combat an illegal global market worth up to $200 billion annually.

New site is expected to complement CDMO’s commercial production experience.

Acquisition expands company’s eCTD submission capabilities.

Latest investigation signals more scrutiny of pharmacy benefit managers and their role in treatment cost and coverage.

The deal—potentially totaling upwards of $100 million—strengthens the company’s selection of US generic prescription products.

Stats point to a 14.9% decline compared to January of last year.

Initiative intends to facilitate regulatory compliance within the pharma distribution space.

With the help of traceability, new feature prioritizes efficiency and safety, from production to patient.

Hoping to accelerate the drug delivery process, production is expected to begin as early as 2025.

Following numerous successful trial runs, vaccine production is expected to reach 700 million.

Expansion expected to increase global capacity by 75%.

Enhancements to help keep products frozen for over 144 hours, company says.

Joint venture revolves around around the use of raw materials for the development—and ultimately commercialization—of therapies.

New 25,000 square-foot facility will help grow customers’ gene therapy programs.